FDA CRDAC backs Merck's antiplatelet vorapaxar
This article was originally published in Scrip
Executive Summary
An FDA panel of advisers on 15 January voted 10-1 to back approval of Merck’s vorapaxar, an antagonist of the protease-activated receptor-1, as an adjunctive therapy to reduce atherothrombotic events in patients with a history of myocardial infarction (MI).